A gut-heart connection in cardiometabolic regulation.
A gut-heart connection in cardiometabolic regulation.
复制标题
DOI：
10.1038/nm.3196
复制
发表时间：
2013-05
期刊：
影响因子：
82.9
通讯作者：
Burnett JC Jr
中科院分区：
文献类型：
--
作者：
Buglioni A;Burnett JC Jr
GLP-1 R激动剂是治疗2型糖尿病（T2 DM）的新型新药。这些药物（如利拉鲁肽和来自肠道的天然GLP-1）与降压心脏激素心房利钠肽（ANP）的释放之间的有趣联系不仅建立了糖尿病血糖控制的新肠道-心脏联系，而且建立了整体心血管稳态。
GLP-1R agonists are novel new drugs for patients with type 2 diabetes mellitus (T2DM). An intriguing connection between these agents such as liraglutide and native GLP-1 from the gut and the release of the blood pressure lowering cardiac hormone atrial natriuretic peptide (ANP) establishes a new gut – heart connection not only for glycemic control in diabetes, but in overall cardiovascular homeostasis.